News from roche canada A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 13, 2022, 10:00 ET Roche Canada Celebrates 125 Years of Innovation

MISSISSAUGA, ON, May 13, 2022 Ahead of Canada Innovation Week, Roche, one of the world's leading pharmaceutical, in vitro diagnostics, and healthcare technology companies celebrates 125 years of...

Feb 04, 2022, 08:00 ET Health Canada Authorizes TECENTRIQ® (atezolizumab) for Canadians with early non-small cell lung cancer (NSCLC)

In Canada, lung cancer is the most commonly diagnosed cancer, with estimates that 29,600 Canadians received a diagnosis in 20211 Tecentriq® (atezolizumab) is the first and only cancer immunotherapy...

Feb 03, 2022, 08:00 ET Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for EVRYSDIⓇ (risdiplam) for the treatment of adults and children with spinal muscular atrophy (SMA)

MISSISSAUGA, ON, Feb. 3, 2022 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for ...

Aug 30, 2021, 08:00 ET Evrysdi® (risdiplam) Receives CADTH Reimbursement Recommendation for Some Patients with Spinal Muscular Atrophy

The CADTH recommendation is a step in the right direction for the public reimbursement of Evrysdi; however, limits access to treatment for many patients with SMA Canadians now wait more than 450 days ...

May 28, 2021, 08:00 ET Roche Canada Announces Collaboration to Improve Access to Personalized Healthcare with Real World Evidence

BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate cost-effective access to targeted treatments for cancer patients...

Apr 15, 2021, 07:00 ET Health Canada Authorizes EVRYSDI® (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children

SMA is a progressive neuromuscular condition that affects the nerve cells in the spinal cord and impacts the muscles used for activities such as breathing, eating, crawling and walking i ii EVRYSDI®...

Mar 18, 2021, 08:00 ET Roche Canada Artificial Intelligence Centre of Excellence opens digital competition to tackle ALS

MISSISSAUGA, ON, March 18, 2021 /CNW/ - The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative...

Mar 16, 2021, 09:00 ET Health Canada approves Perjeta for use pre-surgery in patients with aggressive early breast cancer[1]

New approval provides Canadian patients with HER2-positive early breast cancer a proven treatment regimen in a neo adjuvant setting where meaningful reductions in tumour size can have long-term...

Sep 24, 2020, 07:00 ET Health Canada Grants Market Authorization to Polivy™ (polatuzumab vedotin) for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma[i]

First-in-class antibody-drug conjugate that specifically targets CD79b and destroys B cells through the delivery of an anti-cancer agent ii,iii MISSISSAUGA, ON, Sept. 24, 2020 /CNW/ - Hoffmann-La...

Aug 31, 2020, 08:00 ET Health Canada Authorizes ENSPRYNG® for Canadians Living with Neuromyelitis Optica Spectrum Disorder

ENSPRYNG is a targeted IL-6R treatment that is administered every four weeks by subcutaneous injection[1] MISSISSAUGA, ON, Aug. 31, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced...

Jun 02, 2020, 07:00 ET Roche Canada Announces Winners of COVID-19 Open Innovation Challenge

Program will fund 11 unique solutions for challenges posed by COVID-19 from Canadians across the country MISSISSAUGA, ON, June 2, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to...

Apr 28, 2020, 08:00 ET Health Canada approves Rozlytrek® (entrectinib) for NTRK gene fusion-positive solid tumours in locally advanced or metastatic patients(1)

Data show more than half of trial patients across all 10 tumour types studied had responses to treatment,2 including in patients where cancer has spread to the central nervous system3 MISSISSAUGA,...

Apr 16, 2020, 07:00 ET Roche Canada Launches Data Science Coalition to Advance COVID-19 Solutions

Coalition created a publicly available centralized repository to enhance research MISSISSAUGA, ON, April 16, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce the launch of ...

Apr 08, 2020, 07:00 ET Roche Canada Launches Data Science Coalition to advance COVID-19 solutions

Coalition created a publicly available centralized repository to enhance research MISSISSAUGA, ON, April 8, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce the launch of...

Mar 31, 2020, 14:30 ET Roche Canada establishes COVID-19 Open Innovation Challenge

All Canadians invited to develop solutions for challenges posed by COVID-19 MISSISSAUGA, ON, March 31, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce the launch of the...

Nov 20, 2019, 09:51 ET New Report Reveals Major Gaps in Quality of Care for Canadians with Rare Lung Disease

Burden of Idiopathic Pulmonary Fibrosis in Canada report sheds light on barriers to treatment and resources for Canadians living with this debilitating condition MISSISSAUGA, ON, Nov. 20, 2019 /CNW/...

Aug 13, 2019, 08:00 ET Health Canada approves Tecentriq® (atezolizumab), first new treatment in 20 years for aggressive form of lung cancer(1)

Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung cancer live longer, with a 30% reduction in the risk of death2 MISSISSAUGA, ON,...

Jun 18, 2019, 07:59 ET Health Canada Approves Hemlibra® for Hemophilia A Patients Without Factor VIII Inhibitors

Hemlibra is the only treatment that can be self-injected subcutaneously once weekly for patients with hemophilia A without factor VIII inhibitors1 MISSISSAUGA, ON, June 18, 2019 /CNW/ - Hoffmann-La...

Mar 19, 2019, 10:00 ET Roche and the pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for Multiple Sclerosis Treatment, OCREVUS® (ocrelizumab), for both RRMS and PPMS

MISSISSAUGA, ON, March 19, 2019 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter...

Sep 13, 2018, 08:00 ET HERCEPTIN® (trastuzumab) subcutaneous (SC) formulation approved in Canada for the treatment of HER2-positive breast cancer

SC formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous (IV) formulation MISSISSAUGA, ON, Sept. 13, 2018 /CNW/ - Hoffmann-La Roche Limited...

Aug 07, 2018, 08:00 ET Health Canada Approves HEMLIBRA® for Hemophilia A Patients with Inhibitors

HEMLIBRA is the first new treatment in almost 20 years for this most severe form of hemophilia1 and the only medicine that is self-injected once weekly MISSISSAUGA, ON, Aug. 7, 2018 /CNW/ -...

Aug 07, 2018, 08:00 ET Health Canada Approves HEMLIBRA® for Hemophilia A Patients with Inhibitors

HEMLIBRA is the first new treatment in almost 20 years for this most severe form of hemophilia1 and the only medicine that is self-injected once weekly MISSISSAUGA, ON, Aug. 7, 2018 /CNW/ -...

Jul 09, 2018, 08:00 ET Health Canada Approves GAZYVA® for Previously Untreated Advanced Follicular Lymphoma

GAZYVA is the first anti-CD20 treatment in 15 years for the most common subtype of indolent lymphoma.1 MISSISSAUGA, ON, July 9, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today...

Feb 15, 2018, 08:00 ET Health Canada Approves OCREVUS® (ocrelizumab) for Canadians Living with Primary Progressive Multiple Sclerosis (PPMS)

OCREVUS is a new treatment for a rare and worsening form of MS that impacts 10-15 per cent of Canadians living with the disease1 MISSISSAUGA, ON, Feb. 15, 2018 /CNW/ - Hoffmann-La Roche Limited...

Nov 02, 2017, 08:00 ET Health Canada Approves ACTEMRA® (tocilizumab) for Canadians Living with Giant Cell Arteritis (GCA)

ACTEMRA® is the first non-steroid treatment designed to directly target the interleukin-6 (IL-6) receptor, offering a new option to treat GCA1 MISSISSAUGA, ON, Nov. 2, 2017 /CNW/ - Hoffmann-La Roche...